03.25.20
Researchers recently published the introduction of a study in the British Medical Journal that they intend to conduct to determine whether annatto tocotrienol can have positive health effects on postmenopausal women, using DeltaGold Tocotrienols.
Tocotrienols, members of the vitamin E family, typically make up a smaller portion of vitamin E supplements, compared to a greater portion of tocopherols. Both tocopherols and tocotrienols can be referred to as vitamin E, and both have antioxidant properties. Tocotrienols are typically sourced from rice, palm, and annatto, and research suggests that tocopherols may inhibit the absorption and beneficial functions of tocotrienol. The vitamin E family is made up of a total of four tocopherols and four tocotrienols.
Dr. Barrie Tan, president of American River Nutrition, said that he was “pleased to see this first-ever tocotrienol clinical trial on an obese population commence.”
“This study attempts to quantify the role of tocotrienol in human adiposity in novel ways, measuring not only the amount of adipose tissue, but also the adipose tissue bioavailability, adipose inflammation, and weight loss,” Tan continued.
A six-month randomized, double-blind, placebo-controlled trial will be conducted at Texas Tech University Health Sciences Center, and will utilize DeltaGold annatto-derived tocotrienol by American River Nutrition. It will be the first-ever clinical trial on an obese human population to determine changes in fat mass, visceral adipose tissue, lipid profile, metabolism-related gene expression, fatty acid metabolites, and the gut microbiome. In total, the study participants will be 60 postmenopausal women who are obese.
The participants will each receive either a placebo, or a 300 mg dose of tocotrienol daily over the six-month period.
Researchers are intrigued with the potential that tocotrienols have as an anti-inflammatory agent, and believe that the benefits applied to inflammatory processes in fat cells could assist in weight loss and overall metabolic improvements. In an unrelated studym, participants suffering from non-alcoholic fatty liver disease lost weight after taking 600 mg tocotrienols per day.
Due to an unsaturated side chain, tocotrienol more effectively penetrates tissues, and can be found in association with lipoproteins, fat deposits, and cellular membranes. Its attributes, identified in a wide range of animal and clinical studies, along with a good safety profile, suggest that tocotrienol could aid in an individual’s effort to control obesity.
The primary outcome measure will quantify fat mass and visceral adiposity in the trunk, legs, and arms. Additionally, the study will analyze participant’s blood serum and adipose tissue samples to test hs-CRP and lipid profiles, pro-inflammatory adipokines, and oxidative stress markers, with a specific focus on antioxida and oxidative stress metabolites. This is prefaced by a clinical trial in 2018 which showed that annatto tocotrienol reduced one oxidative stress marker, 8-OHdG, in postmenopausal women with osteopenia by nearly 50%.
Obessity is a major health concern in postmenopausal women, who experience it at higher rates than the U.S. population as a whole, according to the CDC. Healthy diet and increased exercise remain the leading strategies in preventing and fighting obesity across all populations.
Tocotrienols, members of the vitamin E family, typically make up a smaller portion of vitamin E supplements, compared to a greater portion of tocopherols. Both tocopherols and tocotrienols can be referred to as vitamin E, and both have antioxidant properties. Tocotrienols are typically sourced from rice, palm, and annatto, and research suggests that tocopherols may inhibit the absorption and beneficial functions of tocotrienol. The vitamin E family is made up of a total of four tocopherols and four tocotrienols.
Dr. Barrie Tan, president of American River Nutrition, said that he was “pleased to see this first-ever tocotrienol clinical trial on an obese population commence.”
“This study attempts to quantify the role of tocotrienol in human adiposity in novel ways, measuring not only the amount of adipose tissue, but also the adipose tissue bioavailability, adipose inflammation, and weight loss,” Tan continued.
A six-month randomized, double-blind, placebo-controlled trial will be conducted at Texas Tech University Health Sciences Center, and will utilize DeltaGold annatto-derived tocotrienol by American River Nutrition. It will be the first-ever clinical trial on an obese human population to determine changes in fat mass, visceral adipose tissue, lipid profile, metabolism-related gene expression, fatty acid metabolites, and the gut microbiome. In total, the study participants will be 60 postmenopausal women who are obese.
The participants will each receive either a placebo, or a 300 mg dose of tocotrienol daily over the six-month period.
Researchers are intrigued with the potential that tocotrienols have as an anti-inflammatory agent, and believe that the benefits applied to inflammatory processes in fat cells could assist in weight loss and overall metabolic improvements. In an unrelated studym, participants suffering from non-alcoholic fatty liver disease lost weight after taking 600 mg tocotrienols per day.
Due to an unsaturated side chain, tocotrienol more effectively penetrates tissues, and can be found in association with lipoproteins, fat deposits, and cellular membranes. Its attributes, identified in a wide range of animal and clinical studies, along with a good safety profile, suggest that tocotrienol could aid in an individual’s effort to control obesity.
The primary outcome measure will quantify fat mass and visceral adiposity in the trunk, legs, and arms. Additionally, the study will analyze participant’s blood serum and adipose tissue samples to test hs-CRP and lipid profiles, pro-inflammatory adipokines, and oxidative stress markers, with a specific focus on antioxida and oxidative stress metabolites. This is prefaced by a clinical trial in 2018 which showed that annatto tocotrienol reduced one oxidative stress marker, 8-OHdG, in postmenopausal women with osteopenia by nearly 50%.
Obessity is a major health concern in postmenopausal women, who experience it at higher rates than the U.S. population as a whole, according to the CDC. Healthy diet and increased exercise remain the leading strategies in preventing and fighting obesity across all populations.
